<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01183442</url>
  </required_header>
  <id_info>
    <org_study_id>ENM-DA012</org_study_id>
    <nct_id>NCT01183442</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in CAD and Postchallenge Hyperglycemia</brief_title>
  <official_title>Effects of Vitamin D Supplementation in Coronary Artery Disease Patients With Postchallenge Hyperglycemia and Vitamin D Deficiency on Endothelial Function and Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the investigation is to clarify, whether vitamin D supplementation in
      coronary artery disease patients with vitamin D deficiency and postchallenge hyperglycemia
      has an impact on endothelial dysfunction and parameters of insulin sensitivity and beta-cell
      function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An improvement of endothelial dysfunction as a cardiovascular surrogate parameter could be
      translated in a reduced risk for future cardiovascular events, which is of major interest,
      since patients with postchallenge hyperglycemia face a significantly higher cardiovascular
      risk than patients with normal glucose tolerance. Furthermore an improvement in insulin
      sensitivity and/or beta-cell function would identify vitamin D as an important strategy for
      the prevention of type 2 diabetes. In consideration of the rapidly increasing prevalence of
      diabetes and the failure of current prevention strategies this could be an important, safe
      and cheap way to support ongoing lifestyle modifying programs. Our study of course
      investigates surrogate cardiovascular and insulin sensitivity parameters. Assuming a
      beneficial effect of vitamin D in our study, this concept would have to be proven in further
      large outcome as well as diabetes prevention trials.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unable to recruit
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial dysfunction</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in endothelial dysfunction (peripheral artery tone (PAT) and biochemical)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin resistance and beta-cell function</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in indices for insulin resistance and beta-cell function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Postprandial Hyperglycemia</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>vitamin D (Oleovit®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vitamin D drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D</intervention_name>
    <description>orally administered 2800 IU of vitamin D or placebo daily</description>
    <arm_group_label>vitamin D (Oleovit®)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>vitamin d (Oleovit®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40-75

          -  Postchallenge hyperglycemia (2h-whole blood glucose value in oral glucose tolerance
             test above 119 mg/dl, normal fasting glucose)

          -  Angiographically verified coronary artery disease (&gt;50% stenosis)

          -  Serum 25-OH- vitamin D &lt; 20 ng/ml in winter/spring/autumn and &lt;25 ng/ml during
             june-september

          -  Stable antihypertensive therapy in the last 3 month

        Exclusion Criteria:

          -  Acute coronary syndrome or cerebrovascular event within the previous 1 month

          -  BMI &gt; 40 kg/m²

          -  Serum creatinine &gt;2.5 times the upper limit of normal

          -  GOT or GPT &gt; 3 times the upper limit of normal

          -  Heart failure &gt; NYHA class II

          -  Uncontrolled hypertension (&gt;160/100 mmHg)

          -  New onset of statins, ACE-inhibitors or ARBs within the previous 4 weeks

          -  History of urolithiasis

          -  Hypercalcaemia

          -  Major psychiatric disorders

          -  Ongoing treatment with spironolactone, canrenoate, eplerenone, amiloride, triamterene
             and aliskiren.

          -  Treatment with antipsychotic drugs

          -  Regular significant antioxidants, vitamins or protein supplementation

          -  Immunosuppressive therapy

          -  Glucocorticoid therapy

          -  Ongoing chemotherapy

          -  Pregnancy

          -  Any other disease with an estimated life expectancy below 1 year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R. Pieber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Graz, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Internal Medicine, Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2010</study_first_submitted>
  <study_first_submitted_qc>August 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

